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We previously reported a randomized controlled trial in
which 227 de novo deceased-donor kidney transplant
recipients were randomized to rabbit antithymocyte
(rATG, Thymoglobulin) or daclizumab if they were
considered to be at high immunological risk, defined
as high panel reactive antibodies (PRA), loss of a first
kidney graft through rejection within 2 years of trans-
plantation, or third or fourth transplantation. Patients
treatedwithrATGhad lower incidencesofbiopsy-proven
acute rejection (BPAR)andsteroid-resistant rejectionat1
year. Patientswere followed to 5 years posttransplant in
an observational study; findings are described here.
Treatmentwith rATGwasassociatedwitha lower rateof
BPAR at 5 years (14.2% vs. 26.0% with daclizumab;
p¼ 0.035). Only one rATG-treated patient (0.9%) and one
daclizumab-treated patient (1.0%) developed BPAR after
1year. Five-yeargraftandpatientsurvival rates,andrenal
function, were similar between the two groups. Overall
graft survival at 5 years was significantly higher in
patients without BPAR (81.0% vs. 54.8%; p< 0.001). In
conclusion, rATG is superior to daclizumab for the
prevention of BPAR among high-immunological-risk
renal transplant recipients. Overall graft survival at
5 years was approximately 70% with either induction
therapy, which compares favorably to low-risk cohorts.
Abbreviations: AR, acute rejection; ATG, antithymo-
cyte globulin; BPAR, biopsy-proven acute rejection;
CDC, complement dependent cytotoxicity; CI, confi-
dence interval; GFR, glomerular filtration rate; HLA,
human leukocyte antigen; HR, hazard ratio; IL-2Ra, IL-2
receptor-antagonizing monoclonal antibodies; MDRD,
Modification of Diet in Renal Disease; MMF, mycophe-
nolate mofetil; OR, odds ratio; PRA, panel reactive
antibodies; PTLD, posttransplant lymphoproliferative
disorder; SD, standard deviation
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Introduction
Acute rejection after kidney transplantation is amajor cause
of allograft dysfunction and can lead to rapid loss of graft
function despite anti-rejection therapy. Even when kidney
function initially recovers, acute rejection is associatedwith
an increased risk of long-term graft failure (1). Acute
rejection is, accordingly, a well-established surrogate
endpoint for long-term outcomes. High-quality evidence
has shown that induction therapy with a biological agent
lowers the risk of acute rejection, and it is therefore widely
administered as part of the early immunosuppressive
regimen (2,3). In recipients at low immunological risk (i.e.
patients with no previous exposure to human leukocyte
antigens [HLA]) either lymphocyte-depleting polyclonal
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antithymocyte globulin (ATG) or non-depleting IL-2 receptor
monoclonal antibodies (IL-2Ra) are equally effective in
preventing acute rejection (3). For patients at high risk for
delayed graft function and/or acute rejection, however, ATG
is superior to IL-2Ra for the prevention of biopsy-proven
acute rejection (BPAR) in the first year after kidney
transplantation (4,5).
In the TAXI study (4), we randomly assigned 227 high-
immunologic risk patients prior to kidney transplantation
from a deceased donor to either rabbit ATG (rATG) or
daclizumab if they met one of the following risk factors:
current panel reactive antibodies (PRA) >30%; peak PRA
>50%; loss of a first kidney graft from rejection within
2 years of transplantation; or two or three previous grafts.
Compared with the daclizumab group, patients treated with
rATGhad a lower incidence of bothBPAR (15.0%vs. 27.2%;
p¼ 0.016) and steroid-resistant rejection (2.7% vs. 14.9%;
p¼ 0.002) at 1 year. Rates of graft and patient survival were
also similar between the two groups (4). Graft and patient
survival are themost important clinical endpoints but require
clinical studies with long follow-up and very large sample
sizes todetect anydifferencesbetween treatment regimens
and are therefore rare in kidney transplantation. A recent
meta-analysis of randomized controlled trials (5–9) that
provided outcomes data to at least 5 years posttransplant
found no differences between treatment with IL-2Ra and
ATG (3) but the limited patient numbers meant that the
analysis lacked statistical power to detect relatively small
differences in graft or patient survival. Furthermore, the vast
majority of includedpatientswere at low immunological risk.
Since the advantages of rATG in preventing acute rejection
are focused on highly immunized recipients, the long-term
effect may be different in this subgroup.
After completion of the TAXI trial, patientswere followed to
5 years posttransplant in an observational study. We report
these 5-year results here.
Materials and Methods
Study design
The objective of this observational follow-up study was to compare the
efficacy and safety of rATG and daclizumab in patients at high risk of acute
rejection to 5 years posttransplant.
This investigator-driven study was undertaken at 16 French and three
Belgian centers and was approved by the institutional review board at each
site in Belgium and by the Comite´ de Protection des Personnes dans la
Recherche Biome´dicale in France. The design, data collection, analysis and
writing were performed by the investigators. Written informed consent was
obtained from all patients. The study was registered at the Cochrane Renal
Group database (CRG020600038). The core TAXI study was a 1-year,
prospective, randomized trial. Patients were assigned to receive either rATG
or daclizumab before transplantation, according to a 1:1 central randomiza-
tion procedure. Stratification was performed for patients with current PRA
>80%. Each patient also received maintenance therapy comprising
tacrolimus, mycophenolate mofetil (MMF) and steroids. After ending the
randomized study at 1 year posttransplantation, patients were followed in an
observational manner.
Inclusion and exclusion criteria
Adult renal transplant recipients (18–70years) assigned to receiveasinglekidney
graft from a deceased donor were eligible for the study if one or more of the
Figure 1: Patient disposition.
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following risk factors were present: (i) a current anti-HLA PRA30% (assessed
by complement dependent cytotoxicity [CDC] test), (ii) peak PRA 50%
(assessedbyCDC test), (iii) patients scheduled for a second transplantation after
losing a first graft due to rejection within 2 years posttransplant, or (iv) a third or
fourth kidney graft, irrespective of HLA sensitization.
The main exclusion criteria were receipt of a multiorgan or a previous non-
renal transplant or transplantation from a donor after cardiac death.
Transplantations were performed only if the cytotoxic dependent cross-
match from serum sampled on the day of transplantation was negative. Any
additional cross-matching techniques and HLA matching selection policy
were undertaken according to center practice.
Immunosuppression and concomitant medications
rATG (Thymoglobulin
1
, Genzyme, Cambridge, MA) was administered daily
between day 0 and day 7 at a dose of 1.25mg/kg/day. Five injections of
daclizumab (Zenapax
1
, Roche, Basel, Switzerland) were administered at a
dose of 1mg/kg on days 0, 14, 28, 42 and 56. Methylprednisolone was
administered on days 0 (500mg intravenously) and 1 (250mg intravenously),
followed by oral doses of 16mg/day during days 2–15, 12mg/day during
days 16–30, 10mg/day during days 31–60, 8mg/day during days 61–90, and
then 0.1mg/kg up to 1 year. MMF (CellCept
1
, Roche, Basel, Switzerland)
was administered at a dose of 2 g/day during months 1 and 2 and could
subsequently be reduced to 1.5 g/day during month 3 and 1 g/day thereafter
according to individual center practice. In the daclizumab group, tacrolimus
(Prograf
1
, Astellas, Tokyo, Japan) was initiated at a dose of 0.2mg/kg before
transplantation. In the rATG group, tacrolimus was initiated on day 2 and
delayed until up to day 5 if there was no spontaneous decrease in serum
creatinine. Target tacrolimus trough levels were 10–15 ng/mL for the first 3
months posttransplant and then 8–12 ng/mL up to 1 year.
Study endpoints
The primary endpoint of the core TAXI study was the proportion of patients
with BPAR by 1 year posttransplant. Rejection severity was scored
Table 1: Baseline characteristics of organ recipients and donors
rATG (n¼106) Daclizumab (n¼104) p-value
Male, n (%) 48 (45.3) 58 (54.7) 0.50
Age at transplantation, years 44.910.3 47.39.0 0.08
Cause of ESRD, n (%) 0.79
Glomerulonephritis 49 (46.2) 43 (41.3)
Uropathy 10 (9.4) 14 (13.5)
Autosomal dominant polycystic kidney disease 10 (9.4) 10 (9.6)
Diabetes 3 (2.8) 1 (1.0)
Other 22 (20.8) 21 (20.2)
Unknown 12 (11.3) 15 (14.4)
Number of HLA mismatches
HLA A 0.90.8 0.90.7 0.66
HLA B 1.10.8 1.20.8 0.48
HLA DR 0.90.8 0.90.8 0.84
First graft, n (%) 30 (28.3) 32 (30.8) *
Current PRA, % 3532 3733 0.82
Peak PRA, % 7720 7821 0.79
Second graft, n (%) 55 (51.9) 52 (50.0) *
Current PRA, % 3528 4031 0.39
Peak PRA, % 6923 7518 0.14
Third or fourth graft, n (%) 21 (19.8) 20 (19.2) *
Current PRA, % 2632 2931 0.74
Peak PRA, % 6032 6722 0.40
All patients
Current PRA, % 3330 3732 0.38
Peak PRA, % 6925 7520 0.10
Cold ischemia time, hours 24.18.1 22.46.4 0.12
Donor
Male, n (%) 70 (66.0) 60 (57.7) 0.21
Age, years 43.913.9 44.113.8 0.95
Death from stroke, n (%) 51 (48.1) 42 (40.4) 0.26
Cytomegalovirus serologic status, n (%) 0.64
DþRþ 36 (34.0) 41 (39.4)
DþR- 16 (15.1) 12 (11.5)
D-Rþ 41 (38.7) 36 (34.6)
D-R- 12 (11.3) 15 (14.4)
Continuous variables are shown as mean  SD.
rATG, rabbit antithymocyte globulin; ESRD, end-stage renal disease; HLA, human leukocyte antigen; PRA, panel reactive antibodies; SD,
standard deviation.
*Number of patients receiving a first versus second versus third or fourth graft: p¼0.9.
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according to the Banff 1997 criteria (10). Borderline changes suspicious for
acute rejection (mild tubulitis) were categorized as BPAR if the patient was
treated for acute rejection. All patients were followed until death or until
year 5 after transplantation regardless of graft loss.
Endpoints for this 5-year follow-up study were:
– Proportion of patients with BPAR to year 5 posttransplant;
– Patient and graft survival at year 5;
– Causes and risk factors for graft loss;
– Renal function at year 5, evaluated by serum creatinine levels and
estimated glomerular filtration rate (eGFR) according to the abbreviated
Modified Diet in Renal Disease (MDRD) formula;
– Proteinuria and blood pressure at year 5; and
– Immunosuppressive therapy at year 5.
Statistical analysis
All study endpoints were analyzed according to the intention-to-treat (ITT)
principle. Categorical data were compared with the use of Pearson’s
Chi-squared test, and continuous variables were compared with the use of
Table 2: Graft function, blood pressure, and immunosuppressive therapy in patients with a functioning graft at year 5 posttransplant (n ¼
146)
rATG (n¼73) Daclizumab (n¼73) p-value
eGFR (MDRD), ml/min/1.73m2 (n¼142) 48.9  19.0 53.0  19.3 0.21
Proteinuria n ¼ 441 n ¼ 431
>0.5 g/L (n¼20) or >0.5 g/24 h (n¼67) 7 (15.9%) 16 (37.2%) 0.030
Blood pressure
Number of antihypertensive drugs (n¼111) 1.6  1.1 1.8  1.0 0.56
Systolic blood pressure, mmHg (n¼121) 13417 13714 0.83
Diastolic blood pressure (mmHg) (n¼120) 7810 8010 0.15
Immunosuppressive therapy n¼621 n¼651
Tacrolimus, n (%) 53 (85.5%) 64 (98.5%) 0.008
Mean (median) tacrolimus trough level, ng/mL 6.8 (6.6) 7.3 (7.2) 0.45
Cyclosporine, n (%) 6 (9.7%) 0 (0%) 0.012
Sirolimus, n (%) 4 (6.4%) 3 (4.6%) 0.71
MMF, n (%) 54 (87.1%) 47 (72.3%) 0.048
Mean (median) MMF dose (mg/day) 1107 (1000) 1227 (1000) 0.42
Azathioprine, n (%) 1 (1.6%) 3 (4.6%) 0.61
Steroids, n (%) 49 (79.0%) 49 (75.4%) 0.62
Mean (median) prednisone dose (mg/day) 5.8 (5.0) 6.0 (5.0) 0.96
Number of immunosuppressive drugs 0.13
Triple therapy 43 (69.3%) 40 (61.5%)
Dual therapy 19 (30.6%) 21 (32.3%)
Monotherapy 0 (0%) 4 (6.2%)
Significant p-values are shown in bold.
Continuous variables are shown as mean  SD.
rATG, rabbit antithymocyte globulin; GFR, glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; MMF, mycophenolate
mofetil; SD, standard deviation.
1Number of patients with available data.
Figure 2: Probability of BPAR (Kaplan–
Meier analysis).
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the t test or Mann–Whitney U test, as appropriate. Survival free of BPAR
rejection, death-censored graft loss or death was calculated by Kaplan–
Meier analysis and compared between groups using the log-rank test. A
p-value of less than 0.05 was considered statistically significant. Cox
regression analysis was used to test the relationship between independent
(nominal or continuous) covariates and a dependent nominal variable.
Covariates were limited to those with p< 0.05 in the univariate analysis to
avoid overfitting of the model.
Results
Patient characteristics and demographics
In total, 240 patients were assessed at 19 sites in France
and Belgium during the period from May 2001 to
November 2005, of whom 227 entered the trial (Figure 1).
By year 5, 17 patients were lost to follow-up such that 210
patients (92.5%; 106 rATG, 104 daclizumab) could be
analyzed. The groups were well balanced with respect to
demographics and baseline characteristics (Table 1).
Patients were broadly sensitized against HLA antigens,
as reflected by amean current PRA of 35% and a peak PRA
of 72%. Approximately 40% of patients had a peak PRA
above 80%. Sixty-two patients (29.5%) were receiving a
first graft, 107 (51.0%) a second graft, 38 (18.1%) a third
graft and three (1.4%) a fourth graft. Fifteen patients (7.1%)
had a current PRA <30% and a peak PRA <50% but were
still considered at high immunological risk because eight
were recipients of a third graft and sevenwere recipients of
a second graft after rejection of the previous graftwithin the
first 2 years. At 12months,meanMMFdosewas 1.3 g/day,
mean methylprednisolone dose was 7mg/day and mean
tacrolimus trough level was 8.8 ng/mL. At 5 years, the
majority of patients were still receiving MMF, methylpred-
nisolone and tacrolimus (Table 2).
Efficacy endpoints
By year 5, BPAR had occurred in 15 rATG patients (14.2%)
and 27 daclizumab patients (26.0%) (p¼ 0.035, odds ratio
[OR] 0.47, 95%confidence interval [CI] 0.22–0.95) (Figure2,
Table 3). Only one patient in the rATG group and one patient
in the daclizumab group developed BPAR after 1 year of
transplantation.
Five-year overall graft survival in the rATG and daclizumab
groups was 68.9% and 70.2%, respectively (p¼ 0.84, OR
1.1 [95% CI 0.59–1.92]). The rate of death-censored graft
survival was 76.4% and 75.0%, respectively (p¼ 0.81, OR
Table 3: Efficacy endpoints at 1 and 5 years after transplantation

























þ1 27 (26.0%) þ1 0.47
(0.22–0.95)
0.035




þ18 31 (29.8%) þ16 1.1
(0.59–1.92)
0.84
From death with functioning graft 3 (2.8%) 3 (2.9%) 8 (7.5%) þ 5 5 (4.8%) þ2
From acute rejection 5 (4.7%) 4 (3.8%) 5 (4.7%)
(þ0)
þ0 5 (4.8%) þ1
From chronic rejection, allograft
glomerulonephritis
0 (0%) 1 (1.0%) 6 (5.7%) þ6 7 (6.7%) þ6
From chronic allograft nephropathy
without signs of rejection
0 (0%) 0 (0%) 5 (4.7%) þ5 5 (4.8%) þ5
From recurrence of initial kidney disease 1 (1.0%) 0 (0%) 2 (1.9%) þ1 1 (1.0%) þ1
From technical causes 3 (2.8%) 2 (1.9%) 3 (2.8%) þ0 2 (1.9%) þ0
From other causes 1 (1.0%) 3 (2.9%) 2 (1.9%) þ1 4 (3.8%) þ1
From unknown causes 2 (1.9%) 2 (1.9%) 2 (1.9%) þ0 2 (1.9%) þ0
Death 4 (3.8%) 3 (2.9%) 1.32
(0.29–6.05)
0.72 9 (8.5%) þ5 8 (7.7%) þ5 1.1
(0.41–3.01)
0.83
From cardiovascular cause 0 (0%) 0 (0%) 2 (1.9%) þ2 2 (1.9%) þ2
From infectious cause 1 (1.0%) 2 (1.9%) 1 (1.0%) þ0 3 (2.9%) þ1
From cancer 1 (1.0%) 0 (0%) 2 (1.9%) þ1 0 (0%) þ0
From posttransplant
lymphoproliferative disease
0 (0%) 0 (0%) 0 (0%) þ0 1 (1.0%) þ1
From other cause 0 (0%) 1 (1.0%) 1 (1.0%) þ1 1 (1.0%) þ0
From unknown cause 2 (1.9%) 0 (0%) 3 (2.8%) þ1 1 (1.0%) þ1
CI, confidence interval; OR, odds ratio; rATG, rabbit antithymocyte globulin.
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0.93 [95% CI 0.49–1.74]), and the rate of patient survival
was 91.5%and 92.3%, respectively (p¼ 0.83,OR 1.1 [95%
CI 0.41–3.01]) (Figure 3, Table 3). There were no apparent
differences in the reasons for graft loss or death between
the two groups (Table 3).
One hundred and forty-six patients had a functioning graft at
year 5, among whom serum creatinine level at year 5 was
available in 142 cases. In these patients, serum creatinine
(meanSD) at year 5was 1.6 0.7mg/dl in the rATGgroup
versus 1.50.6 in the daclizumab group. eGFR (mean
SD, MDRD) was similar in the two groups (Table 2).
Proteinuria data at year 5, available for 87/146 patients,
showed a significantly higher proportion of patients with
proteinuria >0.5 g/L or >0.5 g/24 h in the daclizumab group
(37.2% vs. 15.9% in the rATG group; p¼ 0.030). At year 5,
systolic blood pressure, diastolic blood pressure and the
number of different antihypertensive drugs taken daily was
similar in both groups (Table 2).
To determine whether BPAR exerted a negative impact on
graft survival, a post hoc analysis was performed based on
the total study cohort to compare patients with BPAR
(n¼42) with those who remained rejection-free (n¼ 168).
Death-censored graft survival at 5 years was 54.8% in
patients who had experienced BPAR versus 81.0% among
rejection-free patients, (p< 0.001) (Figure 4). Other risk
factors for graft lossat 5 yearsonunivariate analysis included
older donor age (p¼ 0.010), third or fourth graft versus first
graft (p¼ 0.010), a higher number of HLA mismatches
(p¼0.027) and the occurrence of delayed graft function
(p¼0.006). Multivariate analysis confirmed that donor age,
Figure 3: (A) Probability of freedom from
death-censored graft loss; (B) probability of
survival (Kaplan–Meier analyses).
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third or fourth grafts and the number of HLA mismatches
were independent risk factors for graft loss (Table 4).
Discussion
To date, the TAXI trial is the only large randomized study to
compare induction with rATG or IL-2Ra specifically in highly
immunized kidney transplant recipients. This follow-up
study provides the largest prospectively-collected dataset
so far on long-term graft survival in this selected population.
The particularly high immunological risk of this cohort is
confirmed by themean peak and current PRA levels of 72%
and 35%, respectively, with almost three-quarters of
patients receiving a second, third or fourth graft. Further-
more, we should keep in mind that at the time that patients
were enrolled in the study, highly sensitive immunoassay
monitoring to detect HLA antibodies (e.g. flow cytometry,
Luminex, or ELISA) was not performed. It is therefore likely
that a proportion of these highly immunized patients were
transplanted with donor-specific antibodies.
The most remarkable finding is that despite a difficult
clinical course in the first year after transplant with a high
frequency of BPAR, especially in the daclizumab group,
long-term outcomes in these high-risk patients were not
markedly dissimilar from those in lower-risk recipients.
Firstly, BPAR was rare after the first year posttransplant.
Thus, surprisingly, this immunosuppression regimen was
adequate in these high-risk patients with only good
compliance to a standard maintenance regimen even
though no systematic biopsies were performed and there
was no monitoring of HLA antibodies. Secondly, overall
5-year graft survival was approximately 70%. Although this
is lower than 5-year graft survival rates reported recently for
first transplants from deceased donors in Europe
(78% (11)), it is comparable—and even higher—than
5-year graft survival following a first transplant from a
deceased donor in white Americans (71%) and African
Americans (63%) (12). Our findings also show that the
number of HLA mismatches remains an important risk
factor for graft loss in highly immunized patients.
The incidence of BPAR remained significantly lower with
rATG induction than daclizumab induction at 5 years
posttransplant, consistent with results at 1 year (4). There
was no significant difference in 5-year graft survival, but the
study was not powered to detect such a difference. A post-
hoc analysis showed that 5-year graft survival was
significantly lower in patients who experienced BPAR. A
recent systematic review showed that the occurrence of
acute rejection is associated with an increased risk of graft
loss across a broad range of patients at different levels of
immunological risk and receiving various concomitant
immunosuppressive regimens (1). It is therefore likely
that acute rejection is also an important surrogate endpoint
for graft survival for patients at high immunological risk.
Proteinuria is another well-documented risk factor for graft
loss (13). Since the incidence of proteinuria>0.5 g/day was
significantly higher in the daclizumab subgroup, this may
suggest aworse long-term prognosis in daclizumab-treated
patients. Larger study populations and longer follow-up (>5
years) may be required to identify any difference in graft
survival using rATG versus daclizumab induction.
However, even discounting a possible benefit for graft
survival, reducing the number and severity of acute
rejection episodes by using rATG as compared to IL-2Ra
induction lowers the risks, costs and psychological stress
inherent to acute rejection episodes. Managing acute
rejection typically requires a kidney biopsy, hospitalization
and additional immunosuppressive therapy such as high-
dose corticosteroids or, in cases of steroid-resistant and/or
Figure 4: Probability of death-censored
graft loss according to presence or
absence of BPAR (Kaplan–Meier analysis).
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antibody-mediated rejection, the use of rATG, intravenous
immunoglobulin, plasma exchange, eculizumab or anti-
CD20 antibodies (2). In a prospective randomized pilot trial
comparing rATG or daclizumab induction therapy in 22
immunologically high-risk kidney recipients, Kim et al (14)
showed that the costs for hospitalization per day at 2 years
posttransplant was approximately five times higher in the
daclizumab group, resulting in an average cost-difference of
more than 10000 USD per patient. Popat et al (15) also
showed that following kidney transplantation from a donor
after cardiac death the use of rATG versus IL-2Ra induction
resulted in significant cost savings (for example due to less
frequent BPAR, shorter bed stays and fewer clinic visits in
the first years after transplantation).
In some respects, our study can be compared to the trial by
Brennan and colleagues, who performed a prospective
randomized trial with rATG versus IL-2Ra induction in
patients at high risk for delayed graft function and/or acute
rejection (5,16). In contrast to our study, only 10% of
patients enrolled in that trial were retransplants and peak
and current PRA values were 14% and 6%, respectively.
The study was carried out in centers throughout both
Europe and theUS (compared to only France andBelgium in
our trial), and donor and recipient age was higher, with a
longer cold ischemia time. Despite these differences,
however, the results of Brennan et al closely mirrored our
findings. During the first year, acute rejection rates were
lower in the rATG group (15.6% vs. 25.5% with IL-2Ra





Univariate analysis Multivariate analysis2
HR (95% CI) p HR (95% CI) p
Induction therapy3
ATG 50% 49% 0.99 (0.75–1.30) 0.95
Daclizumab 50% 51%
Recipient age (meanSD) 45.89.9 46.59.5 1.01 (0.98–1.04)4 0.59
Male recipient, % 45.9% 52.9% 1.30 (0.75–2.26) 0.35
Donor age, years 42.214.5 48.511.0 1.03 (1.01–1.05)4 0.010 1.03 (1.01–1.05)4 0.015
Male donor, % 65.8% 51% 0.60 (0.34–1.03) 0.065
Cold ischemia time, hours 23.37.3 22.87.7 0.99 (0.96–1.03)5 0.73
Graft number6 Overall: 0.037 Overall: 0.056
First graft 35% 18%
Second graft 49% 53% 1.95 (0.92–4.14) 0.083 1.64 (0.77–3.50) 0.078
Third or fourth graft 16% 29% 2.95 (1.29–6.75) 0.010 2.22 (0.96–5.14) 0.017
Current PRA7
 30% 51% 48%
> 30% 49% 52% 1.08 (0.62–1.89) 0.78
Peak PRA8
 50% 17% 22%
> 50% 83% 78% 0.79 (0.40–1.54) 0.49
Primary nephropathy Overall: 0.70
Glomerulonephritis 42.5% 45%
Uropathy 12% 12%





HLA mismatches (0–6) 2.81.5 3.31.5 1.23 (1.02–1.47)9 0.027 1.23 (1.02–1.48)9 0.029
Delayed graft function 32.2% 52.0% 2.17 (1.25–3.78) 0.006 1.68 (0.95–2.98) 0.073
Continuous variables are shown as meanSD. Significant p-values are shown in bold.
CI, confidence interval; HLA, human leukocyte antigen; HR, hazard ratio; PRA, panel reactive antibodies.
1Excluding patients who died with a functioning graft.
2Cox regression analysis.
3Reference: daclizumab.
4Unit change for HR: 1 year.
5Unit change for HR: 1 hour.
6Reference: first graft.
7Reference: Current PRA 30%.
8Reference: Peak PRA 50%.
9Unit change for HR: per mismatch.
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induction, p¼ 0.02) and after the first year, acute rejection
became rare in both arms (<5%). As in our study, they
found no difference in 5-year graft or patient survival rates
(69% vs. 63% [p¼ 0.63] and 76% vs. 80% [p¼ 0.59]
respectively), based on the subgroup of US patients.
With regard to safety, rATG has historically been
associated with an increased risk of infection or malignan-
cy compared to IL-2Ra (3). However, we did not observe
any difference in 5-year patient survival, nor any sugges-
tion of increased mortality from infection or malignancy in
the rATG arm. In addition, although the risk of posttrans-
plant lymphoproliferative disorder (PTLD) was reported to
reach 1% in patients receiving rATG at 3 years after
transplantation during the mid-1980s to early 2000s (17) (a
significantly higher proportion than in patients given IL-
2Ra induction), only one patient in the current study died
of posttransplant lymphoma within 5 years, in the
daclizumab induction group. Our findings are also in line
with those of Brennan et al, which showed a lower
incidence of treated cytomegalovirus infection in the rATG
group and no significant differences in malignancy or
PTLD (16). One reason for the similar rates of infectious
complications or malignancy with rATG or IL-2Ra therapy
in these high-risk patients may lie in the higher rate of
acute rejection and steroid-resistant acute rejection in the
daclizumab group. These patients received additional anti-
rejection immunosuppression, lowering the difference in
overall immunosuppressive intensity between the two
arms. Given the apparent positive balance of benefits
versus harm, the results of this study support the current
Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines, which suggest using rATG rather than IL-2Ra
induction in highly immunized patients (2).
Alemtuzumab is a monoclonal antibody which, like rATG,
strongly depletes T-lymphocytes in humans. It has been
shown to reduce BPAR compared to IL-2Ra induction, but
not compared to ATG (18). This has been established in
patients with ‘low’ and ‘intermediately high’ immunological
risk (18,19). Graft and patient survival appear to be similar
with either alemtuzumab or rATG. Data on infection or
malignancy risks in alemtuzumab-treated patients remain
limited (18). Even if alemtuzumab and ATGwere equivalent
in high-risk patients, which is as yet untested in a head-to-
head comparison, it is not commercially available in Europe
due to legal and administrative reasons.
There are several notable limitations to our study. Firstly, the
observational designof the follow-upstudy inherently implies
that uncontrolled treatment modifications could occur,
limiting the power of the statistical comparisons. Secondly,
since 17patients (7.5%of theoriginal study population)were
lost to follow-up at 5 years, preferential selection of patients
with better outcomes cannot be ruled out.
Today, the approach tomanaging highly immunized patients
has broadened. There is growing experience with desensiti-
zation protocols, paired-kidney donation and new pharma-
cological options such as eculizumab (20). Technical
advances in antibody characterization using sensitive bead
immunoassays and the C1q assay can help to guide
therapeutic strategies. However, these newer therapeutic
and diagnostic tools are often complex and expensive, and
their optimal clinical use has not yet been defined. Recent
studies have focused primarily on HLA-incompatible trans-
plantation, but the definition of humoral incompatibility
remains subjective: apart from ‘‘clear-cut’’ CDC-positive
cross-match, studies often include CDC cross-match nega-
tive subjects with a positive cross-match based on flow
cytometry or solid-based immunoassays (20,21). As
mentioned above, it is likely that a proportion of patients in
this study had (CDC-negative) donor-specific antibodies at
the time of transplantation or developed them afterwards.
Nevertheless, this study indicates that with only rATG or IL-
2Ra induction and tacrolimus-based triple maintenance
therapy, long-term outcomes in highly immunized patients
are not markedly dissimilar from those of their lower-risk
counterparts. When investigating newer therapeutic strate-
gies in high-immunological risk patients, including CDC-
negative HLA incompatible transplant recipients, a treatmen
t protocol similar to that used here and incorporating rATG
induction should be considered the ‘‘standard’’ comparator.
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